Drugs / AMG 595
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01475006 | Feb 2012 → Apr 2016 | anaplastic astrocytoma, glioblastoma | Amgen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01475006 ↗ |
| Modality | Other / unclassified | “AMG 595 is an antibody drug conjugate” NCT01475006 ↗ |
| Target | EGFR | “binds to EGFRvIII” NCT01475006 ↗ |